2025-01-14 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its innovative medicines and vaccines.  The cumulative return of MRK (66.71%) lags behind the S&P 500 (VOO) cumulative return (112.47%) by 45.8 percentage points. This places MRK's relative performance at the 16th percentile based on historical data, indicating underperformance compared to the broader market.  The provided alpha consistently shows negative values (-0.1), suggesting underperformance relative to the market benchmark.  Beta values fluctuate significantly, implying variable sensitivity to market movements.  Market capitalization (Cap(B)) shows a steady increase over time.

**2. Recent Price Movement:**

* **Closing Price:** 100.98
* **5-Day Moving Average:** 100.16
* **20-Day Moving Average:** 99.65
* **60-Day Moving Average:** 100.81

The current price is slightly above the 5-day and 20-day moving averages, suggesting a recent upward trend, but below the 60-day average, indicating potential short-term momentum but possible longer-term stagnation.

**3. Technical Indicators & Expected Return:**

* **RSI:** 56.28 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.1995 (Positive, suggesting bullish momentum)
* **Relative Divergence (20-day):** +6.1% (Short-term upward trend)
* **Expected Return (Long-term):** 31.8% (Significant expected outperformance relative to the S&P 500 over a 2+ year investment horizon).


The current price (100.98) is not significantly deviating from recent averages. It does not reflect a sharp surge or drop, suggesting a relatively stable price movement.  The high expected return, however, should be viewed with caution and within the context of inherent investment risks.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-11-06 | 1.25  | $16.66B      |
| 2024-08-05 | 2.15  | $16.11B      |
| 2024-05-03 | 1.88  | $15.78B      |
| 2023-11-03 | 1.87  | $15.96B      |
| 2024-11-06 | 1.87  | $15.96B      | *(Duplicate entry - likely a data error)*


Earnings show some volatility.  A significant drop in EPS is observed in November 2024 (1.25 vs. previous quarters' figures around 1.8).  Revenue remains relatively stable, indicating consistent performance despite fluctuations in profitability.  The duplicate entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |
| 2023-09-30 | $15.96B    | 73.29%        |

Revenue shows consistent growth with some minor fluctuations.  Profit margins are generally high and stable, though showing some quarter-to-quarter variability.

**Capital and Profitability:**

| Quarter    | Equity     | ROE          |
|------------|------------|--------------|
| 2024-09-30 | $44.50B    | 7.09%        |
| 2024-06-30 | $43.58B    | 12.52%       |
| 2024-03-31 | $40.36B    | 11.80%       |
| 2023-12-31 | $37.58B    | -3.26%       |
| 2023-09-30 | $41.25B    | 11.50%       |

Equity has shown a general upward trend, though there is some fluctuation. ROE shows significant variability, with a notably negative value in Q4 2023.


**7. Overall Analysis:**

MRK shows mixed signals. While the long-term expected return is promising and revenue remains stable with high profit margins, the recent underperformance against the S&P 500, negative alpha, and the volatility in earnings and ROE raise some concerns.  The recent price movement suggests short-term upward momentum, but longer-term trends need further observation. The accuracy of the projected 31.8% return depends heavily on various market factors and future performance.  Further investigation into the causes of the EPS drop and ROE fluctuations is crucial before making any investment decisions.  Independent financial advice is recommended.

**8. Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Investment decisions should be made based on thorough research and consideration of individual risk tolerance.
